Back to top
more

Johnson & Johnson (JNJ)

(Real Time Quote from BATS)

$165.30 USD

165.30
1,333,573

-2.06 (-1.23%)

Updated Sep 5, 2024 12:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Mark Vickery headshot

Top Research Reports for February 1, 2017

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), PayPal (PYPL) and Thermo Fisher (TMO).

    Madeleine Johnson headshot

    Stock Market Roundup Jan. 31: Nasdaq Rebounds Amid Trump Biotech Meeting

    Following the trend set yesterday, U.S. stocks closed mostly lower on Tuesday but still managed to record monthly gains. Investors continue to weigh the latest policies from the Trump Administration as well as companies' results from the current earnings season.

      Ryan McQueeney headshot

      Biotech Stocks Gain on Latest Trump Drug Price Statements

      President Trump continues to double down on his campaign promises, and his latest statements regarding drug prices and regulation have sent biotech stocks higher on Tuesday.

        Kinjel Shah headshot

        Pfizer (PFE) Q4 Earnings Lag, Sales Top; '17 Sales View Soft

        Pfizer, Inc. (PFE) missed earnings estimates in the fourth quarter.

          Swarup Gupta headshot

          Dow 30 Stock Roundup: Boeing, Caterpillar, Johnson & Johnson, DuPont Beat on Earnings

          The Dow gained over the week following continuing optimism over Trump's first actions as President and encouraging earnings results.

            Merck (MRK): Stock to Gain on Likely Earnings Beat in Q4?

            We expect pharma heavyweight Merck & Co., Inc. (MRK) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Feb 2.

              J&J to Acquire Actelion for $30B: Is It a Strategic Fit?

              Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Actelion (ALIOF) for $280 per share, as of Jan 25, 2017, in an all-cash transaction.

                Madeleine Johnson headshot

                For $30 Billion, Johnson & Johnson is Acquiring Swiss Biotech Actelion

                On Thursday, healthcare giant Johnson & Johnson (JNJ) announced it will acquire Swiss biotechnology company Actelion for $30 billion in order to boost its roster of rare disease treatments.

                  Biogen (BIIB) Q4 Earnings Top Estimates; '17 Sales View Soft

                  Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, reported mixed fourth-quarter 2016.

                    The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb

                    The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb

                      What Lies in Store for Pfizer (PFE) this Earnings Season?

                      Pfizer Inc. (PFE) will be reporting fourth-quarter and full-year 2016 earnings results on Jan 31, before market open.

                        Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY

                        How will these three drug stocks, CELG, BMY and BIIB, which are all scheduled to report Q4 results on Jan 26, fare this earnings season?

                          Eric Dutram headshot

                          Is Customer Satisfaction the Hidden Key to Stock Outperformance?

                          In this edition of the Dutram Report, we take a closer look at the idea of customer satisfaction. Do companies that serve their customers better end up being more impressive investments? In order to get to the bottom of this, I spoke with Kevin Quigg, Chief Strategist of ACSI Funds for some answers and insights.

                            Sunesis Offers Updates on SNS-062 and Qinprezo Programs

                            Sunesis (SNSS) provided updates on two of its lead programs: SNS-062, and Qinprezo (vosaroxin).

                              Can AbbVie (ABBV) Spring a Surprise This Earnings Season?

                              AbbVie Inc. (ABBV) is slated to release fourth-quarter and full-year 2016 earnings results before the opening bell on Jan 27.

                                Mark Vickery headshot

                                Q4 Earnings Roundup: JNJ, VZ, MMM, DD, Etc.

                                Ahead of the opening bell today, we have plenty of Q4 earnings results to report.

                                  J&J (JNJ) Q4 Earnings Top; Seeks Options for Diabetes Unit

                                  Johnson & Johnson (JNJ) reported a mixed quarter with earnings beating expectations while sales missing the same.

                                    The Zacks Analyst Blog Highlights: Goldman Sachs, DuPont, Johnson & Johnson, Verizon Communications and Travelers Companies

                                    The Zacks Analyst Blog Highlights: Goldman Sachs, DuPont, Johnson & Johnson, Verizon Communications and Travelers Companies

                                      J&J (JNJ) Beats on Q4 Earnings, Sales Miss; Stock Down

                                      JNJ beat on fourth quarter earnings - the company reported EPS of $1.58 while our consensus called for EPS of $1.56.

                                        Tracey Ryniec headshot

                                        The Best Earnings Charts on the Street

                                        It's not easy to beat on earnings every quarter for years but these companies are doing it.

                                          Swarup Gupta headshot

                                          Dow Stocks to Watch for Earnings on Nov 24: DD, JNJ, TRV, VZ

                                          The nature of these releases is likely to determine the fortunes of the Dow in the days ahead.

                                            Sweta Killa headshot

                                            Can Q4 Earnings Revitalize Healthcare ETFs?

                                            The Q4 earnings could bring some near-term relief given that the sector is expected to post earnings growth of 2.9% and revenue growth of 5.6%.

                                              5 Best Performing Healthcare Mutual Funds of 2016

                                              Investors rely on the healthcare firms to safeguard their investments as demand for its services does not vary much with market conditions

                                                J&J Arm Buys Megadyne, Boosts Electrosurgical Tools Portfolio

                                                Ethicon Endo-Surgery, Inc. a subsidiary of Johnson & Johnson (JNJ), announced the acquisition of Megadyne Medical Products, Inc., a privately held medical device company.

                                                  What's in Store for Abbott Labs (ABT) This Earnings Season?

                                                  Abbott Laboratories (ABT) is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.